Phosphodiesterase-3 inhibitor (inotrope/vasodilator)
Enoximone
Brand names: Perfan
Adult dose
Dose: Loading 0.5–1mg/kg IV slowly; infusion 5–20 micrograms/kg/min titrated
Route: IV
Frequency: Continuous infusion
Clinical pearls
- Short-term decompensated HF / cardiogenic shock — ICU/CCU only
- Largely superseded by milrinone in many UK centres
- ESC HF acute decompensation guidance — inotropes for cardiogenic shock with hypoperfusion
Contraindications
- Severe outflow obstruction (HOCM, severe AS)
- Hypovolaemia (correct first)
- Hypersensitivity
Side effects
- Hypotension
- Arrhythmias (ventricular and supraventricular)
- Thrombocytopenia
- Headache
- Nausea
Interactions
- Other inotropes/vasodilators
- QT-prolonging drugs
Monitoring
- Continuous ECG
- BP
- Cardiac output
- Platelets
- Electrolytes
Reference: BNF; ESC acute HF guidelines; AAGBI ICU; SmPC; https://bnf.nice.org.uk/drugs/enoximone/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines